Company: RPTX
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030405
Chunk: 98

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 98
---
,900

        $
        2,743

        December 31,

        2024

        2023

        (in thousands, except as specified otherwise)

        Other Operating Lease Information

        Operating cash flows for operating leases
         
        $
        2,441

        $
        2,405

        Right-of-use assets obtained in exchange for lease obligations
         
        $
        957

        $
        149

        Weighted-average remaining lease term (in years)

        0.90

        1.46

        Weighted-average discount rate

        7.9
        %

        4.2
        %
       
      Variable lease costs for the years ended December 31, 2024 and 2023 include contingent rental usage, common area maintenance and other operating charges. Future minimum lease payments under the Company’s operating leases as of December 31, 2024 were as follows: 

        December 31,2024

        (in thousands)

        Maturity of Lease Liabilities

        2025
         
        $
        1,913

        2026

        88

        Thereafter

        —

        Total lease payments
         
        $
        2,001

        Less: interest

        (68
        )

        Total lease liabilities
         
        $
        1,933

11. Shareholders’ Equity Preferred SharesEffective upon the closing of the IPO, the Company authorized for issue an unlimited number of preferred shares, issuable in series, having such designations, rights, privileges, restrictions and conditions, including dividend and voting rights as the board of directors of the Company may determine, and such rights and privileges, including dividend and voting rights, may be superior to those of the common shares. No preferred shares were issued and outstanding as of December 31, 2024 and 2023.Common SharesThe articles of continuance of the Company authorize an unlimited number of common shares, voting and participating, without par value. 

119

Each common share entitles the holder to one vote on all matters submitted to the shareholders for a vote. The holders of common shares are entitled to receive dividends, as may be declared by the board of directors, if any. Through December 31, 2024, no dividends have been declared or paid. In August 2022, the Company entered into a sale agreement (the “2022 Sales Agreement”), with Cowen and Company, LLC